Tectora, a biotech focused on immunology and inflammation therapies, secured $55 million in Series A funding.
Amount Raised
$55 Million
Round Type
Series A
Description
Tectora, a biotech company focused on immunology and inflammation therapies, has closed a Series A funding round of $55 million. The company was formed with support from Schrödinger, a computational chemistry platform. This funding will support Tectora's development of therapies in immunology and inflammation. The news has drawn attention to Schrödinger's role in the biotech ecosystem.
Who else raised in Biotechnology and Health Care around the same time
Companies in the same sectors as Tectora that raised within 45 days of this round, from Fundz verified event records.
- Lifeplex Science raised $5.3M (Series A) on November 13, 2026.
- Orakl Oncology raised $34M (Series A) on November 12, 2026.
- Skribe Medical raised $1.6M (Pre-Seed) on November 12, 2026.
- BioWraptor raised $1.5M (Pre-Seed) on November 12, 2026.
- Neurosterix raised $105M (Series B) on November 11, 2026.
- Kardi Ai raised $5.9M (Series A) on November 11, 2026.
Who to call at Tectora, and when
A new round usually means Tectora is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Tectora raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Tectora, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Tectora. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Tectora raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
What this usually meansTectora raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.